The primary objective of this research was to assess the effectiveness of a single ascending dosage of NTLA-2001 in treating patients with polyneuropathic hATTR amyloidosis through TTR editing and knockout in human hepatocytes (Gillmore et al., 2021). This evidence concerns the gene TTR and familial amyloid neuropathy.